PDCD1 and cancer: Recently, immune checkpoint inhibitors (ICIs), specifically programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) antibodies, have demonstrated considerable potential in treating various types of cancer such as melanoma, non-small cell lung cancer, and renal cell cancer.